Dragonfly Therapeutics Inc, a clinical stage biotechnology company, announced on Tuesday that it has dosed its first subject in a Phase 1/1b study of the firm's proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumours.
DF6215 is the second in a pipeline of cytokines Dragonfly is developing to address the high unmet need in patients with advanced cancer and other diseases. This is the seventh Dragonfly-developed and fourth Dragonfly-owned drug, in the clinic.
Dragonfly's DF6215 Phase 1/1b clinical trial is a first-in-human, multi-part, open-label study to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of DF6215 in patients with advanced (unresectable, recurrent, or metastatic) solid tumours. DF6215-001 is currently recruiting at multiple sites in the US, with sites in additional regions scheduled to open in 2024.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member